Veeva SystemsWBO:VEEV +5.25%88 ROE % is 14.41% as of Apr. 2026, which is 8% below its 10-year median of 15.62. GuruFocus rates WBO:VEEV with a GF Score™ of 88/100 and a GF Value™ of €246.73 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 625 Healthcare Providers & Services companies, Veeva Systems ranks better than 73.28% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Veeva Systems's annualized net income for the quarter that ended in Apr. 2026 was €892 Mil. Veeva Systems's average Total Stockholders Equity over the quarter that ended in Apr. 2026 was €6,192 Mil. Therefore, Veeva Systems's annualized ROE % for the quarter that ended in Apr. 2026 was 14.41%.
The historical rank and industry rank for Veeva Systems's ROE % or its related term are showing as below:
WBO:VEEV'
s ROE % Range Over the Past 10 Years
Min: 12.58 Med: 15.62 Max: 21.44
Current: 13.68
During the past 13 years, Veeva Systems's highest ROE % was 21.44%. The lowest was 12.58%. And the median was 15.62%.
WBO:VEEV's ROE % is ranked better than 73.28% of 625
companies
in the Healthcare Providers & Services industry
Industry Median: 5.84
vs WBO:VEEV: 13.68
Veeva Systems (WBO:VEEV) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Veeva Systems ROE % Related Terms
Veeva Systems ROE % Historical Data
* Premium members only.
The historical data trend for Veeva Systems's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Veeva Systems's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's ROE % distribution charts can be found below:
* The bar in red indicates where Veeva Systems's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Veeva Systems (WBO:VEEV) has a ROE % of 14.41% as of Apr. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Veeva Systems and its competitors. This is near median its historical median of 15.62. Over the past decade, Veeva Systems' ROE % has ranged from 12.58 to 21.44. According to the industry distribution chart, Veeva Systems ranks #167 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 26.7%.
Is Veeva Systems' ROE % too high?
Veeva Systems' current ROE % of 14.41% is near median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 12.58 to a high of 21.44. The Healthcare Providers & Services industry median ROE % is 5.84. Veeva Systems' value of 14.41% is 146.7% above this industry median. Based on the distribution chart, Veeva Systems ranks #167 out of 625 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Veeva Systems has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' ROE % compare to BTSG and TEM?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #167 out of 625 companies for ROE %. This puts Veeva Systems in the upper half of its industry. The industry median ROE % is 5.84. Veeva Systems' value of 14.41% is 146.7% above this benchmark. Historically, Veeva Systems' own ROE % has ranged from 12.58 to 21.44 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 5.84, Veeva Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current ROE % of 14.41% is 146.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current ROE % is 14.41%, which is near median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (WBO:VEEV) is currently considered Significantly Undervalued. The stock's GF Value™ is €246.73, compared to a current price of €148.25 — trading 39.9% below its estimated fair value. The current ROE % is 14.41%, which is near median its 10-year median of 15.62 and 146.7% above the Healthcare Providers & Services industry median of 5.84. Veeva Systems' overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Veeva Systems (WBO:VEEV), the current ROE % is 14.41% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (WBO:VEEV) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of €148.25 is trading 39.9% below its estimated GF Value™ of €246.73.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for WBO:VEEV:
ROE %: 14.41% (near median its 10-year median of 15.62)
GF Value™: €246.73 vs. price of €148.25 (39.9% below fair value)
Industry Position: 146.7% above the Healthcare Providers & Services median (#167 of 625)
No single metric tells the full story. See the WBO:VEEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
88GF Score
Get the complete analysis for WBO:VEEV
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VEEV has been successfully added to your 
